CareDx Inc (CDNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CareDx Inc (CDNA) has a cash flow conversion efficiency ratio of 0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.33 Million) by net assets ($313.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CareDx Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
CareDx Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how CareDx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CareDx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CareDx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intellect Design Arena Limited
NSE:INTELLECT
|
0.027x |
|
Xinjiang Communications Construction Group Co Ltd Class A
SHE:002941
|
0.089x |
|
Danya Cebus
TA:DNYA
|
-0.046x |
|
AS LHV GROUP EO -10
F:ASU0
|
N/A |
|
Hubei Biocause Pharmaceutical
SHE:000627
|
0.008x |
|
Lindab International AB
ST:LIAB
|
0.071x |
|
Suofeiya Home Collection Co Ltd
SHE:002572
|
-0.038x |
|
Procter & Gamble Health Limited
NSE:PGHL
|
0.278x |
Annual Cash Flow Conversion Efficiency for CareDx Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of CareDx Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see CareDx Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $303.10 Million | $42.03 Million | 0.139x | +37.93% |
| 2024-12-31 | $378.43 Million | $38.05 Million | 0.101x | +242.89% |
| 2023-12-31 | $261.33 Million | $-18.39 Million | -0.070x | -20.13% |
| 2022-12-31 | $430.91 Million | $-25.24 Million | -0.059x | -41.43% |
| 2021-12-31 | $465.88 Million | $-19.29 Million | -0.041x | -134.40% |
| 2020-12-31 | $277.68 Million | $33.43 Million | 0.120x | +530.45% |
| 2019-12-31 | $99.00 Million | $-2.77 Million | -0.028x | +33.04% |
| 2018-12-31 | $95.93 Million | $-4.01 Million | -0.042x | -101.74% |
| 2017-12-31 | $-5.95 Million | $-14.31 Million | 2.403x | +387.38% |
| 2016-12-31 | $19.76 Million | $-16.52 Million | -0.836x | -152.88% |
| 2015-12-31 | $29.49 Million | $-9.75 Million | -0.331x | -307.61% |
| 2014-12-31 | $41.30 Million | $-3.35 Million | -0.081x | -2338.51% |
| 2013-12-31 | $-150.67 Million | $-546.00K | 0.004x | -69.96% |
| 2012-12-31 | $-147.20 Million | $-1.78 Million | 0.012x | -- |
About CareDx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart tr… Read more